Johnson & Johnson's
The company didn't say how long abiraterone was able to extend survival -- it's saving the full data for a scientific meeting in October -- but beating placebo by a statistically significant amount should be enough to get the drug approved, given the lack of options for patients who have failed sanofi-aventis'
Sanofi recently reported data on this patient population for its own second-line drug, cabazitaxel, but the comparison with abiraterone could be difficult. Cabazitaxel produced a median survival of 15.1 months, but the drug was compared to EMD Serono and OSI Pharmaceuticals'
Whichever drug ends up coming out on top, it's clear that Dendreon's
Johnson & Johnson is testing abiraterone in patients earlier in their disease progression, but it's only in a phase 2 trial right now. For the immediate future, Provenge will only have to worry about Taxotere, to which it appears to be superior.
Prostate cancer has generally been considered a tough disease to treat, but recent positive results look like good news for patients. For investors, the results highlight one of the challenges of investing in drugmakers: looking in the rear view mirror -- where you'll find Medivation
Jim Mueller suggests bypassing branded drugs in favor of this generic-drug maker.
Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.
More from The Motley Fool
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
3 Top Value Stocks to Buy in 2018
Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.